GH (guardanthealth.com) Multiplikator EV/Sales

Medicare test approvals have stimulated customer base growth, triggering a sharp spike in the price-to-sales multiple. This metric currently stands at 15920.85. While strategic partnerships with pharma behemoths are accelerating therapy implementation, fierce competition with other biotech firms over marker accuracy creates significant risks for the capitalization of Guardant Health, Inc. (GH).
Guardant Health Inc - rincian analitis lan metrik utama (GH)

This indicator compares the total enterprise value of Guardant Health (GH) to its annual revenue, excluding the impact of debt to reveal true market expectations. Analyzing the company's EV/Revenue ratio allows for an assessment of growth potential amid pricing power constraints caused by strict insurance limits, transforming sales dynamics into an objective tool for the fundamental valuation of investment attractiveness.